Wednesday - July 16, 2025
UT-MD Anderson Cancer Center: ASCO - Pre-surgical Combination Therapy Boosts Survival in Patients With Rare Thyroid Cancer
June 03, 2025
HOUSTON, Texas, June 3 -- The University of Texas MD Anderson Cancer Center issued the following news release:

* * *

ASCO: Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients with rare BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC) compared with historical controls, according . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products